Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Reduced tumor size by 50% in one out of three patients with refractory or relapsed lymphoma.
Subscribe to our email newsletter
Afinitor (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease.
Based on results from this study and other early-stage research, Novartis has initiated a Phase III trial in the most common NHL, diffuse large B-cell lymphoma (DLBCL).
NHL and Hodgkin’s disease, also known as Hodgkin’s lymphoma, refer to a variety of cancers affecting the immune system, such as DLBCL, mantle cell lymphoma and follicular lymphoma.
In the phase II open-label trial, 33% of patients with relapsed NHL and Hodgkin’s disease treated with everolimus, experienced a 50% or greater reduction in tumor size. This 33% overall response rate (ORR) is defined as complete or partial tumor shrinkage.
Alessandro Riva, Executive Vice President and Global Head of Oncology Development at Novartis, said: We continue to see the potential of Afinitor in multiple types of cancer.
These latest data show an antitumor effect in lymphoma that support the rationale for a Phase III study of Afinitor to prevent relapse in patients with diffuse large B-cell lymphoma, where there is a significant unmet medical need, he added.